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Rationale: Early diagnosis of bronchiolitis obliterans syndrome (BOS)
is critical in understanding pathogenesis and devising therapeutic
trials. Although potential-BOS stage (BOS 0-p), encompassing early
changes in FEV1 and forced expiratory flow, midexpiratory phase
(FEF25–75%), has been proposed, there is a paucity of data validating
its utility in single-lung transplantation. Objective: The aim of this
study was to define the predictive ability of BOS 0-p in single-lung
transplantation. Methods: We retrospectively analyzed spirometric
data for 197 single-lung recipients. Sensitivity, specificity, and posi-
tive predictive value of BOS 0-p were examined over time using
Kaplan-Meier methodology. Results: BOS 0-p FEV1 was associated
with higher sensitivity, specificity, andpositive predictive value than
the FEF25–75% criterion over different time periods investigated. The
probability of testing positive for BOS 0-p FEV1 in patients with
BOS (sensitivity) was 71% at 2 years before the onset of BOS. The
probability of being free from development of BOS 0-p FEV1 in
patients free of BOS at follow-up (specificity) was 93% within the
last year. Of patients who met the BOS 0-p FEV1 criterion, 81%
developed BOS or died within 3 years. The specificity and positive
predictive value curves for the BOS0-p FEV1were significantly differ-
ent between patients with underlying restrictive versus obstructive
physiology (p  0.05 and 0.01, respectively). Conclusion: The FEV1
criterion for BOS 0-p provides useful predictive information regard-
ing the risk of development of BOS or death in single-lung recipi-
ents. The predictive value of this criterion is higher in patients with
underlying restriction and is superior to the FEF25–75% criterion.
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Bronchiolitis obliterans is the major complication limiting out-
comes in lung transplantation (1–3). Its clinical correlate, bron-
chiolitis obliterans syndrome (BOS), is defined as a fall in FEV1
of greater than 20% from baseline determined by the average
of two measurements made at least 3 weeks apart (4). Develop-
ment of BOS is associated with progressive irreversible decline
in lung function with a poor response to therapeutic interventions
(1, 2). This feature, and the knowledge that pathogenesis of BO
involves progressive fibroproliferation (2, 5), underscores the
need for early intervention and the need to develop predictors
of this disease.
Implementation of increasingly sensitive criteria for identifying
early decline in pulmonary function may allow the prediction of
BOS. As such, a potential-BOS stage (BOS 0-p), defined by a
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10 to 19% decrease in FEV1 and/or by a 25% or greater decrease
in forced expiratory flow, midexpiratory phase (FEF25–75%), from
baseline was added to the original staging system in 2001 (4).
In bilateral lung transplant recipients, the FEV1 but not the
FEF25–75% criterion for BOS 0-p was shown to be a reasonable
predictor of BOS (6). However, the role of various criteria of
BOS 0-p in predicting recipients with BOS remains to be estab-
lished in single-lung transplant (SLT) recipients. This population
is of particular interest because spirometric criteria, such as FEV1
and FEF25–75%, are influenced by degree and nature of native
lung pathology (7).
This study provides novel data defining the ability of both
FEV1 and FEF25–75% criteria for BOS 0-p to predict development
of BOS in a large cohort of SLT recipients. Some of these results
have been previously reported in the form of an abstract (8).
METHODS
Patients
The study group comprised 197 consecutive SLT recipients who were
alive 3 months post-transplantation and had post-transplant pulmo-
nary functions available. The study was approved by the University of
Michigan Institutional Review Board. All patients were followed by a
standardized protocol as previously described (9). Pulmonary function
testing was performed following standards established by the American
Thoracic Society at each clinic visit (10).
Definition of BOS
Baseline FEV1 and FEF25–75% were determined according to the pub-
lished guidelines (4). The criterion for BOS was met when two consecu-
tive FEV1 values at least 3 weeks apart fell below 80% of baseline
FEV1. Therefore, BOS diagnosis included stages 1, 2, and 3. Medical
records of the patients during this time period were reviewed to exclude
confounding variables, including infection, acute rejection, bronchial
stenosis, and recurrence of primary disease or any other factors that
might explain this decline in lung function. The date of onset of BOS
was defined as the date of the first of the two FEV1 measurements used
to establish the diagnosis.
Definition of BOS 0-p
BOS 0-p was determined by the FEV1 and the FEF25–75% criteria, as
defined by the new guidelines (4), using a similar method as described
above. A modified FEF25–75% criterion for stage 0-p as defined by
Hachem and others (6) in the bilateral lung transplant population was
also analyzed. This modified FEF25–75% redefines the baseline FEF25–75%
as the average of the two FEF25–75% measurements obtained with the
two highest FEV1 measurements (6).
Data Analysis
Correlated times to event were analyzed using years-of-life-saved statis-
tics (11). Kaplan-Meier methodology was used to estimate sensitivity,
specificity, and positive predictive value (PPV) curves for relating the
diagnosis of BOS 0-p by various criteria to development of BOS. These
diagnostic curves are functions of the time between meeting, or not meet-
ing, the BOS 0-p and BOS criteria as well as the available follow-up
window. The appropriate patient population, event time scale, and
follow-up time scale used to construct sensitivity, specificity, and PPV
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curves using the Kaplan-Meier method are detailed further in Table 1.
These same measures were compared between subgroups of SLT recip-
ients with underlying obstructive or restrictive lung disease using
log-rank tests.
To avoid bias from dependent censoring, we studied time to BOS
or death in forward-looking analyses of PPV curves. In estimating
sensitivity and specificity curves, patients were always alive during the
study window; therefore, dependent censoring from death as a compet-
ing endpoint was not an issue.
RESULTS
Primary indications for transplantation for SLT included emphy-
sema with or without 1-antitrypsin deficiency (n  151; 77%)
and interstitial lung diseases (n  34; 18%). The remainder of
the patients (n  12) underwent SLT for miscellaneous indica-
tions. The dataset included 15,118 spirometric observations, with
a mean number of 77  98 observations per patient. Median
follow-up time was 5.4 years (95% confidence interval [CI],
4.6–6.9).
The median time from transplantation to the onset of BOS
or death was 2.27 years (95% CI, 1.84–2.71). The median time
from transplant to the onset of BOS 0-p as defined by FEV1 or
death was 1.84 years (95% CI, 1.53–2.68) (Figure 1); over the
first 5 years of follow-up, this endpoint was observed 65 days
earlier on average than the combined death/BOS endpoint (95%
CI, 18–149 days; p  0.13). The median time from transplant to
the onset of BOS 0-p as defined by the FEF25–75% or death was
1.39 years (95% CI, 1.18–1.61) (Figure 1), observed during the
first 5 years of follow-up 237 days earlier on average than the
combined death/BOS endpoint (95% CI, 161–313 days; p 
2.4  108) and 172 days earlier than the combined death/BOS
0-p as defined by the FEV1 endpoint (95% CI, 81–262 days; p 
0.0003). The median time from transplant to the onset of BOS
0-p as defined by the modified FEF25–75% was 1.59 years (95%
CI, 1.33–1.97) (Figure 1), observed during the first 5 years of
follow-up 158 days earlier on average than the combined death/
BOS endpoint (95% CI, 69–246 days; p 0.0007), 93 days earlier
than the combined death/BOS 0-p as defined by the FEV1 end-
point (95% CI, 3–188 days; p  0.06), and 79 days later on
average than the combined death/BOS 0-p as defined by the
FEF25–75% endpoint.
The sensitivity curves of BOS 0-p by each criterion and the
combinations thereof are illustrated in Figure 2. The most sensi-
tive criterion was the combined criteria of meeting either the
FEV1 or the FEF25–75% criterion. BOS 0-p defined by FEV1 was
the second most sensitive criterion followed by BOS 0-p defined
by FEF25–75%. The probability of testing positive for BOS 0-p in
patients with BOS (i.e., sensitivity) is expected to increase as
longer time periods elapse before onset of BOS. Indeed, 52, 71,
and 84% of patients with BOS had met the BOS FEV1 0-p
criterion within 1, 2, and 4 years before the onset of BOS, respec-
tively. Over a specific time period—for example, within 2 years
TABLE 1. OUTLINE OF KAPLAN-MEIER ELEMENTS THAT WERE USED TO ESTIMATE SENSITIVITY, SPECIFICITY, AND POSITIVE
PREDICTIVE VALUE CURVES
Probability Measurement Patient Population Event Time Scale Follow-up Time Scale
Sensitivity* BOS criteria met Time preceding BOS that BOS 0-p was met Time preceding BOS that transplant was done
Specificity Never met BOS criteria and alive Time before last pulmonary function test Time preceding last pulmonary function test
at end of study that BOS 0-p was met that transplant was done
Positive predictive value* BOS stage 0-p criteria met Time between BOS 0-p and BOS or death Time between BOS 0-p and last follow-up time
Definition of abbreviations: BOS  bronchiolitis obliterans syndrome; BOS 0-p  potential bronchiolitis obliterans syndrome stage.
*Note that Kaplan-Meier estimates were subtracted from 1 in these cases to get the desired probabilities.
before onset of BOS—the sensitivity of FEV1 and FEF25–75%
criteria were 71 and 60%, respectively.
The specificity curves of BOS 0-p criteria are shown in Figure
3. In this case, we examined the population of patients alive and
free of BOS during follow-up and calculated the probability that
they had not met BOS 0-p within t units of time from their last
pulmonary function test. So, for example, if a patient had not
met the BOS criteria during follow-up, there was a 93% chance
that he or she did not meet the BOS 0-p criterion as defined by
FEV1 within the last year. Similarly, there was a 79% chance
that the patient did not meet the BOS 0-p criterion as defined
by FEV1 within the last 4 years. The criterion defined by meeting
FEV1 and FEF25–75% criteria was found to be most specific, fol-
lowed by BOS 0-p defined by FEV1.
As expected, the PPVs increased as follow-up times after
meeting BOS 0-p increased (Figure 4). Within 1 year of meeting
BOS 0-p as defined by FEV1, the probability of meeting BOS
was 56%, and by 4 years, this probability had risen to 86%. The
strongest positive PPVs were observed in those patients who
met either the FEV1 or both the FEV1 and FEF25–75% BOS 0-p
criteria.
Figure 5 compares sensitivity, specificity, and PPV curves in
patients with underlying obstructive lung disease as opposed to
those with underlying restrictive lung disease. The sensitivity
curve for BOS 0-p FEF25–75% was higher in the group with restric-
tive lung disease (p  0.04; Figure 5A). The specificity (Figure
5B) and PPV curves (Figure 5C) for the BOS 0-p FEV1 were
significantly higher for patients with underlying restrictive lung
disease (p  0.05 and 0.01, respectively).
DISCUSSION
BOS affects up to 60% of lung transplant recipients by 5 years
after surgery (1, 2, 12) and is the major cause of mortality after
the first year of transplantation (3). Recent advances in under-
standing pathogenesis point to fibroproliferation as a final com-
mon pathway leading to airway obliteration and progressive
airflow obstruction (2). As such, an early marker of disease is
essential in both treating patients and devising clinical trials with
early intervention. Early changes in pulmonary function can be
one such marker. Although BOS 0-p, encompassing early
changes in FEV1 and FEF25–75%, has been proposed, there is a
paucity of studies validating the usefulness of this new stage in
SLT recipients, a population that comprises more than half of
all lung transplant recipients (3).
This study examined the relationship over time between BOS
0-p and development of BOS in a large cohort of SLT recipients
and the effect of native lung physiology on this prediction. We
demonstrate the following in SLT recipients: (1) the FEV1 crite-
rion of BOS 0-p provides the best combination of sensitivity,
specificity, and PPV over different time periods investigated;
(2) the FEF25–75% criterion lacks sensitivity and specificity as a
Lama, Murray, Mumford, et al.: Predictive Ability of BOS 0-p 381
Figure 1. Freedom from bronchiolitis obliter-
ans syndrome (BOS) and potential BOS stage
(BOS 0-p) by each criterion from the time of
transplantation.
predictor; and (3) native restrictive physiology increases the
diagnostic utility of the FEV1 variable.
An important and clinically relevant finding of our study is
the demonstration that development of BOS 0-p FEV1 in SLT
recipients provides useful prognostic information about subse-
quent development of BOS or death. This is of significant clinical
relevance because predictive ability of the FEV1 criterion has
not been adequately studied previously in SLT recipients. In
addition, the BOS 0-p FEV1 criterion exhibited reasonable speci-
ficity and sensitivity. The combination of either the FEV1 or the
Figure 2. Sensitivity curves of BOS 0-p by each criterion in single-
lung transplant recipients. The sensitivity curve as a function of
time, t, is defined as the probability of having BOS 0-p at t units
of time before onset of BOS among patients who ultimately
develop BOS. The time along the horizontal axis indicates the
length of the time before meeting the BOS criterion.
FEF25–75% criterion was associated with highest sensitivity but
was less specific and predictive. The meeting of both FEV1 and
FEF25–75% criteria was most strongly predictive of development of
BOS or death; however, its utility is limited by its low sensitivity.
Importantly, we document that, in SLT recipients, BOS-0 p
diagnosis by FEF25–75% is associated with lower sensitivity, speci-
ficity, and PPV than the FEV1 criterion. Although in heart-lung
and bilateral lung transplant recipients, an FEF25–75% threshold
of less than 70% of baseline has been shown to be a sensitive
predictor of BOS (13, 14), a recent study found an unacceptably
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Figure 3. Specificity curves of BOS 0-p by each criterion over
time in single-lung transplant recipients. The specificity curve
as a function of time, t, is defined as the probability of not
meeting BOS 0-p criteria within the previous t units of time
from the last pulmonary function test among patients who
were not diagnosed with BOS. The time on the horizontal
axis is the length of time before the last observed pulmonary
function test.
low specificity and PPV of the BOS 0-p FEF25–75% criterion in
bilateral lung transplant recipients (6). In SLT recipients, mea-
surement of FEF25–75% has been associated with higher degree
of variability (7, 15). A study of 43 SLT recipients during a
median follow-up of 16 months reported a sensitivity of the BOS
0-p FEF25–75% of 80% and a specificity of 82.6% for subsequently
detecting BOS stage (16). The differences in findings regarding
predictive ability of the FEF25–75% criterion may reflect the larger
sample size of our study, the longer follow-up time, and differing
statistical techniques used.
Another intriguing finding of our study is that SLT recipients
with underlying restrictive physiology demonstrated a higher
specificity and predictive ability of the BOS 0-p FEV1 criterion
in suggesting subsequent development of BOS. It can be ex-
pected that the native lung physiology will influence the diagnos-
tic ability of criteria based on pulmonary function testing because
of the contribution of the native lung (7). However, because of
the small sample size of our restrictive group, these results will
need to be confirmed in a larger cohort of patients.
A unique feature of our study is that we have examined
sensitivity, specificity, and PPVs as functions of follow-up time
and time between development of BOS 0-p and BOS. As such,
we provide a more complete picture of the diagnostic ability of
BOS 0-p. Our analyses indicate that sensitivity, specificity, and
PPV vary significantly as functions of study-specific parameters,
such as follow-up time and time to development of BOS in the
cohort studied. Using our approach to the analysis of sensitivity,
Figure 4. Positive predictive value of BOS 0-p by each criterion
over time in single-lung transplant recipients (freedom from
BOS or death after the onset of BOS 0-p).
specificity, and PPV is akin to estimating complete survival
curves as opposed to the limited approach of estimating survival
at a single point in time. It is difficult to describe negative pre-
dictive value using BOS 0-p (or any time-dependent testing
measure) because patients negative for BOS 0-p at one point in
time may change to BOS 0-p positive during subsequent follow-
up. As such, it is difficult to identify a solid BOS 0-p–
negative population and still maintain additional follow-up time
to define a negative predictive value.
In summary, the FEV1 criterion for BOS 0-p provides useful
predictive information regarding the subsequent course of pul-
monary function and the risk of development of BOS or death
in SLT recipients. The predictive value of this criterion is higher
in patients with underlying restrictive physiology and is superior
to the FEF25–75% criterion of BOS 0-p. These data demonstrate
the need to be vigilant about onset of BOS 0-p in SLT recipients.
Further studies to document if early intervention at the onset
of this stage changes the natural history of disease are warranted.
Additional studies of factors that influence operating characteris-
tics of BOS-related diagnostic tests also would be useful in mak-
ing clinical predictions. Knowledge of the sensitivity, specificity,
and PPV of this criterion over time can be used in clinical decision
making as well as for designing clinical trials targeting early
disease. We would suggest that the BOS 0-p designation is a
preferable criterion for triggering initiation of therapies in clini-
cal trials of possible disease-modifying agents.
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Figure 5. Sensitivity (A ), specificity (B ), and positive predictive value (C ) for obstructive (solid lines) and restrictive (dashed lines) lung disease for
BOS 0-p defined by both FEV1 (thin lines) and FEF25–75% (bold lines) criteria. The sensitivity for obstructive versus restrictive lung disease was not
significantly different for BOS 0-p FEV1 (p  0.24), but was significantly different for BOS 0-p FEF25–75% (p  0.04). The specificity for obstructive
versus restrictive lung disease was significantly different for BOS 0-p FEV1 (p  0.05), but was not significantly different for BOS 0-p FEF25–75%
(p  0.31). The positive predictive values for obstructive versus restrictive lung disease was significantly different for BOS 0-p FEV1 (p  0.01), but
was not significantly different for BOS 0-p FEF25–75% (p  0.44).
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